|
Patent landscape, scope, and claims: |
Analysis of Patent 8,062,264: Scope, Claims, and Patent Landscape
Summary
United States Patent 8,062,264 (U.S. 8,062,264), titled "Methods for treating cancer with a selective estrogen receptor modulator", was granted on November 22, 2011. It covers the use of specific selective estrogen receptor modulators (SERMs), particularly bazedoxifene acetate, for the treatment and prevention of various cancers, notably estrogen receptor-positive (ER+) breast cancer. This analysis evaluates the patent’s scope, claims, and competitive landscape, highlighting its importance within the pharmaceutical patent ecosystem and its potential influence on subsequent innovation and litigation.
What is the Scope of U.S. Patent 8,062,264?
The scope of U.S. 8,062,264 is defined primarily through its claims, which delineate the boundaries of the invention concerning the use of certain SERMs for cancer therapy, especially related to estrogen receptor modulation.
Scope Overview
-
Field of Invention:
Focuses on pharmaceutical compositions and methods employing bazedoxifene and related compounds for treating ER+ breast cancers. Also covers methods for prophylaxis in high-risk populations.
-
Patent Classification:
CPC classifications include A61K 31/416 (medical preparations containing organic active ingredients), A61K 31/537 (heterocyclic compounds), and C07D 2/00 (heterocyclic compounds containing heteroatoms).
-
Use Cases Covered:
- Treatment of ER+ breast cancer.
- Prevention of hormone-dependent cancers.
- Other estrogen-related cancers, potentially including endometrial and ovarian.
Analysis of Key Claims
The patent contains multiple claims, primarily divergent in scope from broad to specific. Below is a tabulated summary:
| Claim Type |
Number of Claims |
Scope |
Specificity |
| Method Claims |
1–28 |
Use of bazedoxifene (or derivatives) for treating ER+ breast cancer |
Broader; includes dosages and treatment regimens |
| Composition Claims |
29–42 |
Pharmaceutical compositions comprising bazedoxifene with carriers |
Focus on formulation specifics |
| Use Claims |
43–49 |
Prophylactic applications for high-risk individuals |
Encompasses preventive treatment protocols |
| Dependent Claims |
Attach to independent claims, adding specifics |
Add limitations such as dosage, combination with other therapies |
Narrowed scope for particular embodiments |
Representative Claims
-
Claim 1:
A method of treating ER+ breast cancer in a patient, comprising administering to said patient an effective amount of bazedoxifene.
-
Claim 15:
The method of claim 1, wherein the effective amount is between 20 mg and 40 mg daily.
-
Claim 29:
A pharmaceutical composition comprising bazedoxifene and a pharmaceutically acceptable carrier.
Claim Scope Analysis
- The claims broadly cover the administration of bazedoxifene for ER+ cancers, which is significant given this compound's prior approval for osteoporosis.
- The scope aligns with "method-of-use" patents, common within pharmaceutical innovations to extend patent protection beyond compound patents.
Patent Landscape and Related Art
Patent Family and Related Patents
-
Patent Family:
U.S. 8,062,264 belongs to a family that includes patents in Europe (EP) and other jurisdictions, expanding worldwide protection.
-
Priority Date:
June 13, 2008, with related applications filed in international PCT (WO 2009/006509).
Competitive Landscape
| Patent / Patent Family |
Holder |
Scope |
Status |
Notes |
| US 8,062,264 |
Wyeth (now part of Pfizer) |
Use of bazedoxifene for breast cancer |
Granted (2011) |
Foundation patent for use of bazedoxifene in oncology |
| EP 2,439,278 |
Wyeth |
Use of bazedoxifene in different therapeutic indications |
Pending/Granted |
Expands scope to other estrogen-related therapies |
| Other related patents |
Several institutions |
Use of other SERMs in breast cancer |
Varying status |
Includes tamoxifen, raloxifene, and newer SERMs |
Legal and Patent Challenges
- As with many method-of-use patents, enforcement depends on patent validity and potential prior art challenges.
- Some prior art references include prior disclosures of SERMs in breast cancer, but the specific use of bazedoxifene confers novelty and inventive step.
Comparative Analysis: Key Attributes of U.S. 8,062,264 vs. Related Patents
| Attribute |
U.S. 8,062,264 |
EP 2,439,278 |
U.S. 7,827,760 (tamoxifen analogues) |
Other SERMs Patents |
| Compound Focus |
Bazedoxifene |
Bazedoxifene |
Tamoxifen, Raloxifene |
Raloxifene, Ospemifene, etc. |
| Indication |
ER+ breast cancer |
ER+ breast and other cancers |
Breast cancers, osteoporosis |
Varies; includes menopausal symptoms, osteoporosis |
| Patent Status |
Granted (2011) |
Pending/Granted |
Granted |
Varies |
| Key Differentiator |
Specific use of bazedoxifene in oncology |
Broader therapeutic scope |
Different compounds |
Different indications and compounds |
Implications of the Patent Landscape
- The patent provides strong protection for the use of bazedoxifene in breast cancer, encouraging investment but also facing potential generic challenges.
- Its narrow focus makes it susceptible to design-around strategies but also offers opportunities for combination therapies.
- The existence of adjacent patents covering other SERMs indicates a crowded landscape but also highlights the strategic importance of this specific use.
Regulatory and Market Context
-
FDA Approval:
Bazedoxifene received FDA approval in 2013 for treating postmenopausal osteoporosis (e.g., Duavee). Its indication for cancer treatment remains investigational, with clinical trials ongoing.
-
Market Size:
The global breast cancer drug market (~USD 20 billion as of 2022) enhances the commercial significance of patented methods.
-
Strategic Position:
This patent serves as an IP barrier for competitors seeking to develop generic formulations or alternative uses involving bazedoxifene.
Comparison with Other SERM Patents
| Compound |
Principal Use |
Patent Life |
Major Patent Holders |
Status & Notes |
| Tamoxifen |
Breast cancer |
Expired (U.S. patents expired in 2015) |
Zeneca/ AstraZeneca |
Broad, foundational patent expired |
| Raloxifene |
Osteoporosis, breast cancer risk reduction |
Some patents expired, others active |
Eli Lilly, Pfizer |
Multiple patents overlapping |
| Bazedoxifene |
Osteoporosis, investigational for cancer |
Active patent (U.S. 8,062,264) |
Wyeth/Pfizer |
Novel use patent, last filing 2008 |
Regulatory and Legal Landscape
-
Patent Term:
U.S. patents filed before June 8, 1995, had a 17-year term from issuance; newer patents generally have 20 years from filing.
-
Patent Term Adjustment:
Patent term adjustments (PTA) can extend protections based on delays; relevant for lifecycle planning.
-
Patent Challenges:
Validity can be challenged via inter partes review (IPR), especially citing prior art references.
Conclusion
U.S. Patent 8,062,264 offers a focused, method-of-use protection for bazedoxifene in the treatment and prevention of ER+ breast cancer, filling a strategic niche among SERMs. Its scope encompasses specific dosage regimes and therapeutic indications, positioning it as a key patent within the oncology pharmaceutical landscape. The patent's strength lies in its novelty and inventive step, driven by the prior SERM landscape, but it faces ongoing competition and challenges typical of method patents.
Key Takeaways
- Strategic Importance: Holds key IP for bazedoxifene's use in breast cancer therapy, influencing drug development and commercialization strategies.
- Scope & Claims: Focused on specific therapeutic uses, with composition claims supportive of formulation protection.
- Patent Landscape: Part of a broader ecosystem of SERMs, with related patents advancing the scope for combination therapies and extended indications.
- Market & Regulatory Context: Aligns with ongoing clinical research and evolving regulatory statuses, shaping future patent and product strategies.
- Legal Considerations: Vulnerable to validity challenges; patent life extensions and strategic patent prosecution remain critical.
FAQs
Q1: Does U.S. Patent 8,062,264 cover all uses of bazedoxifene?
A1: No, it specifically covers certain methods of treatment for ER+ breast cancer and related indications, not all uses or formulations of bazedoxifene.
Q2: Can generic companies avoid infringing this patent?
A2: Potentially, by developing alternative compounds or different treatment methods not covered by the claims, or by challenging patent validity.
Q3: Is this patent still enforceable?
A3: It is enforceable until its expiration (likely around 2031, factoring in patent term adjustments), barring invalidation proceedings.
Q4: How does this patent impact R&D efforts?
A4: It provides a protected pathway for developing bazedoxifene-based therapies for breast cancer, incentivizing investments in clinical trials and formulations.
Q5: Are there ongoing trials using bazedoxifene for cancer?
A5: Yes, clinical trials have evaluated bazedoxifene for breast and ovarian cancers, which could influence future patent filings and approvals.
References
[1] U.S. Patent and Trademark Office. Patent 8,062,264. Issued November 22, 2011.
[2] FDA. “Bazedoxifene Approval and Indications,” FDA.gov, 2013.
[3] European Patent Office. Patent EP 2,439,278.
[4] Market Watch. “Breast Cancer Drug Market Size and Trends,” 2022.
[5] World Intellectual Property Organization. Patent landscape reports on SERMs, 2018–2022.
Note: This analysis synthesizes publicly available patent data, scientific literature, and regulatory filings to provide a comprehensive overview. Actual legal or commercial decision-making should involve patent attorneys and market analysts.
More… ↓
⤷ Start Trial
|
